About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.55$ per share.

The book value per share is 3.41$

Magenta Therapeutics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -76M - -70M -1.55 - - 36M 3.41 -54M -7M -61M